Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + carfilzomib + pomalidomide + dexamethasone for multiple myeloma with extramedullary disease
ChiCTR2300075691Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selinexor, carfilzomib, pomalidomide and dexamethasone in multiple myeloma (MM) and extramedullary plasmacytoma (EMP), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Overall response rate (ORR). Planned start Oct 2023; status: not yet recruiting.
02
Drugs
selinexorcarfilzomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)extramedullary plasmacytoma (EMP)
Beyond the preview
Go deeper on ChiCTR2300075691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075691.